Introduction Enterococcus spp is responsible for 8%–15% of total bacteraemias with an
associated global mortality around 23%–30%. Regarding the clinical management of …

Methods The INTENSE study is a multicentre, open-label, randomised, pragmatic, phase-IV
clinical trial to demonstrate the non-inferiority of a 7-day vs 14-day course for the treatment of …

Objective To prove that 7-day courses of antibiotics for bloodstream infections caused by
members of the Enterobacterales (eBSIs) allow a reduction in patients' exposure to …

Background The efficacy of vancomycin compared with ampicillin for enterococcal infections
is unknown. This study aimed to compare their efficacy among patients with enterococcal …

Enterococci are a significant cause of bacteraemia in healthcare-associated infections
(HCAI), being resistant to cephalosporins and aminoglycosides often used in this setting …

Objectives The optimal treatment duration for vancomycin-resistant enterococcal (VRE)
bacteraemia is still a matter of debate. The aim of the present study was to compare short …

The duration of antibiotic therapy for bacteremia due to Enterobacteriaceae is not well
defined. We sought to evaluate the clinical outcomes with shorter-versus longer-course …

Background De-escalation from broad-spectrum to narrow-spectrum antibiotics is
considered an important measure to reduce the selective pressure of antibiotics, but a …

Objective of this study was to assess the appropriate treatment duration for enterococcal
central line-associated bloodstream infections (CLABSIs). This observational, retrospective …

Background Enterococcal infections are a significant cause of morbidity and mortality.
Infections caused by vancomycin-resistant enterococci (VRE) are a growing public health …